Infinity Pharmaceuticals Inc (INFI)
0.7347
-0.10 (-11.89%)
USD |
NASDAQ |
Jun 24, 16:00
0.745
+0.01 (+1.40%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 65.50M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -75.83% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 31.98 |
| Price to Book Value | 6.562 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.12% |
News
Headline
Wire
Time (ET)
MT Newswires
05/24 16:54
SA Breaking News
05/23 12:58
MT Newswires
05/23 11:13
Yahoo
05/17 08:35
Yahoo
04/26 08:25
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/02/2022* | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/27/2022* | -- | Results | Q2 2022 | -- | -0.15 | -- | |
| 05/03/2022 | -- | Results | Q1 2022 | -0.14 | -0.14 | -1.95% | |
| 05/03/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/29/2022 | -- | Results | Q4 2021 | -0.13 | -0.14 | 3.85% | |
| 03/29/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/02/2021 | -- | Results | Q3 2021 | -0.12 | -0.14 | 13.38% | |
| 11/02/2021 | 16:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development. |
| URL | https://www.infi.com |
| Investor Relations URL | https://investors.infi.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jul. 27, 2022 (est.) |
| Last Earnings Release | May. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 24, 2022.
Fundamentals
| Revenue (TTM) | 2.043M |
| Total Expenses (TTM) | 47.95M |
| Net Income (TTM) | -46.07M |
| Total Assets (Quarterly) | 72.58M |
| Total Liabilities (Quarterly) | 62.60M |
| Shareholders Equity (Quarterly) | 9.982M |
| Cash from Operations (TTM) | -40.68M |
| Cash from Investing (TTM) | -14.08M |
| Cash from Financing (TTM) | 0.972M |
Ratings
Profile
Edit
| Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development. |
| URL | https://www.infi.com |
| Investor Relations URL | https://investors.infi.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jul. 27, 2022 (est.) |
| Last Earnings Release | May. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| INFI Tweets |